Onxeo shares blitzed after PhIII liver cancer study flops
Shares of Paris-based Onxeo were blitzed after the biotech reported that its Phase III cancer study had failed.
Studying Livatag (doxorubicine Transdrug) in comparison with best standard of care, researchers said that they could see no significant difference on survival scores among patients with inoperable liver cancer who were either intolerant to sorafenib or had progressed on sorafenib.
Onxeo tried hard to explain away the trouble, but its stock {Euronext Paris:ONXEO} plunged by more than half as investors bowed out of a messy situation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.